GBT to Announce Third Quarter 2021 Financial Results on Thursday, November 4
October 28 2021 - 8:00AM
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today
announced that it will report third quarter 2021 financial results
on Thursday, November 4, 2021, after U.S. financial markets close.
Management will host a conference call on
Thursday, November 4, 2021, at 4:30 p.m. ET to discuss third
quarter 2021 financial results and to provide a general business
update. To participate in the conference call, please dial
855-327-6838 (domestic) or +1 604-235-2082 (international). A live
audio webcast can be accessed on GBT’s website at www.gbt.com in
the Investors section. The archived audio webcast will be available
for one month following the event.
The company will also host its R&D Day to
provide an update to the investment community on Oxbryta®
(voxelotor) tablets, the growing body of real-world experience with
the product and GBT’s R&D pipeline, including inclacumab and
GBT021601 (GBT601). The event will be held on Thursday, November
11, 2021, in New York City from 9:00 a.m. to 12:00 p.m. ET. A live
video webcast can be accessed on GBT’s website at www.gbt.com in
the Investors section. The archived video webcast will be available
for three months following the event.
About Global Blood
TherapeuticsGlobal Blood Therapeutics (GBT) is a
biopharmaceutical company dedicated to the discovery, development
and delivery of life-changing treatments that provide hope to
underserved patient communities. Founded in 2011, GBT is delivering
on its goal to transform the treatment and care of sickle cell
disease (SCD), a lifelong, devastating inherited blood disorder.
The company has introduced Oxbryta® (voxelotor) tablets, the first
FDA-approved treatment that directly inhibits sickle hemoglobin
polymerization, the root cause of red blood cell sickling in SCD.
GBT is also advancing its pipeline program in SCD with inclacumab,
a P-selectin inhibitor in Phase 3 development to address pain
crises associated with the disease, and GBT021601 (GBT601), the
company’s next-generation hemoglobin S polymerization inhibitor. In
addition, GBT’s drug discovery teams are working on new targets to
develop the next wave of potential treatments for SCD. To learn
more, please visit www.gbt.com and follow the company on Twitter
@GBT_news.
Contact:Steven Immergut
(media)650-410-3258simmergut@gbt.com
Courtney Roberts
(investors)650-351-7881croberts@gbt.com
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Apr 2024 to May 2024
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From May 2023 to May 2024